{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Phase I - The MTD is defined as the highest dose where less than 33% of participants experience a drug related predefined dose limited toxicity (DLT). Dose-limiting toxicity (DLT) is defined as any grade 4 hematologic toxicity and any grade 3 or greater non-hematologic toxicity except nausea that is controlled by antiemetic therapy based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Grade 3 metabolic/electrolyte abnormalities that are not clinically significant, and are adequately controlled within 72 hours are not to be considered a DLT.","groups":[{"description":"Phase I: Dose Escalation. In Phase I, participants will be allocated to dose levels starting at 10 mg/d (twice a day \\[BID\\] dosing) according to the \"rolling six\" Phase I design.\n\nRuxolitinib: In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.","id":"OG000","title":"I: Dose Escalation - Ruxolitinib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"17 weeks","title":"The Maximum Tolerated Dose (MTD) of Ruxolitinib for the Treatment of Myelomonocytic Leukemia (CMML)","type":"PRIMARY","unitOfMeasure":"mg"}